CHICAGO -- The use of the investigational weekly subcutaneous injection rusfertide significantly reduced the need for ...

Boolean network modeling: The first step toward a new understanding of breast cancer heterogeneity. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include ...

AVEO Oncology, an LG Chem company ("AVEO"), a biopharmaceutical company committed to providing differentiated solutions to improve cancer patients lives, presented three posters during the American ...

China: New research has highlighted that elevated remnant cholesterol (RC) levels are a significant predictor of recurrent ...

The incidence and impact of sepsis in patients hospitalized with cholangiocarcinoma: Findings from the Nationwide Inpatient Sample. Comparison of risk ratios (HRs) and P-values for atrial fibrillation ...

Early use of interferon therapy reduces the risk of secondary myelofibrosis (sMF) in young patients with essential ...

Rusfertide (Protagonist Therapeutics/Takeda Pharmaceuticals) — administered as a once-weekly subcutaneous injection — also ...

The Global Coagulation Monitoring Products Market is expected to reach at a CAGR of 5.6% during the forecast period 2025-2033. The Coagulation Monitoring Products Market is growing due to rising ...

When harmful bacteria or other microorganisms invade the body, neutrophils, a type of white blood cell, are one of the first immune cells to respond. They release powerful weapons to trap and kill ...

US drugmaker Protagonist Therapeutics (Nasdaq: PTGX) and Japan’s Takeda Pharma (TYO:4502) announced detailed results from the ...

Resistant thrombotic thrombocytopenic purpura successfully treated with caplacizumab preceding acute myeloid leukemia Łukasz Mazurkiewicz, Maria M. Joks, Monika Joks, Andrzej Szczepaniak, Lidia Gil, ...

The drug has been reported previously to cause neuropathy and hypersensitivity reactions in breast cancer patients.